Conversations and the Code: Misinformation, Disinformation and Information Gaps in relation to Prescription Medicines

Health Misinformation Crisis

Australia's pharmaceutical sector faces mounting pressure from the rapid spread of misinformation and disinformation about prescription medicines. Driven by AI tools and social media algorithms, false claims about drug efficacy, side effects, and alternatives have proliferated since 2025. The Australian Communications and Media Authority reported in November 2025 that most Australians encounter online misinformation, with health topics among the hardest hit. This surge builds on lingering issues from the COVID-19 era but has intensified with generative AI creating convincing fake medical advice.

Regulatory bodies are responding amid growing evidence of harm. The Therapeutic Goods Administration (TGA), Australia's medicines regulator, rolled out compliance principles in January 2026 focusing on proactive enforcement in the digital landscape. These include countering AI-generated misinformation through education for consumers, healthcare professionals, and industry. Key areas under scrutiny encompass erectile dysfunction drugs, melatonin, and vaping products, with risks amplified by influencer endorsements and black-market sales. Penalties for violations, as seen in the TGA's June 2025 court action against firms illegally advertising medicinal cannabis, can reach millions in fines.

Patients bear the brunt of these information gaps. Vaccine hesitancy, fueled by misleading social media content, has led to measles outbreaks in early 2026, reversing decades of public health gains. Doctors report spending more time debunking myths, straining resources. The tragic case of 24-year-old Erin, who overdosed in 2025 after obtaining stockpiled medications from multiple telehealth providers without coordinated records, underscores the stakes. Her death catalyzed the Federal Government's creation of a National Medicines Record in January 2026, mandating prescribers to log all patient medications to prevent such oversights.

Pharma companies navigate a tightrope under the Medicines Australia Code of Conduct. Edition 20, launched in March 2025, clarifies ethical media engagement but highlights tensions: firms cannot promote prescription drugs to the public, yet face ethical imperatives to correct falsehoods. Responding risks accusations of indirect promotion, while silence allows harm to fester. Internationally, most countries bar public drug advertising—unlike the US—complicating global firms' strategies. Meanwhile, tech platforms' retreat from voluntary misinformation codes in late 2025, amid political backlash against proposed federal laws, leaves gaps in content moderation.

Broader trade-offs emerge in balancing regulation with free expression. The Albanese Government's abandoned 2024 Misinformation Bill aimed to enforce platform transparency but drew fire for potential overreach. Critics argue self-regulation fails, as evidenced by platforms like X withdrawing from fact-checking during the 2023 Voice referendum. Surprising data from a 2025 scoping review shows interventions like platform fact-checking reduce overuse of unproven treatments, yet implementation lags in Australia compared to Canada or the EU.